12. A method for eliciting an immune response in a subject, comprising [the steps of immunising] immunizing the subject with a 5T4 antigen.

13. A method [for eliciting an immune response in a subject, comprising the steps of immunising the subject with a nucleic acid encoding 5T4 antigen, and expressing the 5T4 antigen in the subject] according to claim 12, wherein said 5T4 antigen is expressed in the subject.

14. A method according to claim 12 [or claim 13], wherein the 5T4 antigen is a [modified 5T4 antigen according to any one of claims 5 to 8] peptide epitope of 5T4 antigen and wherein said antigen induces a CTL response.

15. A method [for eliciting] according to claim 13, wherein said immune response is an immunotherapeutic response [in a subject, comprising the steps of immunising the subject with a nucleic acid encoding 5T4 antigen, and expressing the 5T4 antigen in the subject].

16. A method according to [any one of claims 12 to 15] claim 12, wherein the immune response is a CTL response or an antibody response.

18. [Use of 5T4 antigen in the preparation of a composition for the breaking of] A method according to claim 13, wherein said immune response comprises breaking the immune tolerance to 5T4 antigen in said subject.

19. [Use of 5T4 antigen in the preparation of a composition for] A method according to claim 13, wherein said immune response results in [the sterilisation] sterilization of [a] the subject.

20. [Use according to any one of claims 17 to 19] A method according to claim 13, wherein the 5T4 antigen is delivered by means of a viral vector [according to any one of claims 1 to 3] expressing a nucleic acid encoding 5T4 antigen.

A3 cancel.

21. [Use according to any one of claims 17 to 20] A method according to claim 13, wherein the 5T4 antigen is a modified 5T4 antigen [according to any one of claims 5 to 8].

Claim 24, line 2, replace "tumour" with --tumor--.

27. A poxvirus vector [having] according to claim 24, which has a reduced lytic activity [and from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a TAA].

A4

28. A vector according to [any of claims] claim 24 [to 27] which is not MVA.

29. A vector according to [any one of claims] claim 24 [to 28] which is replication deficient.

30. A vector according to [any one of claims] claim 24 [to 29], wherein the TAA is selected from the group consisting of melanoma-associated antigens (MAAs), melanocyte differentiation antigens [such as MART-1 and gp100], MAGE-1, MAGE-3, CEA, tyrosinase, mutant ras, mutant [and] p53, CA-125, PSA, c-erbB2, and 5T4.

A5

32. A method for eliciting an immune response in a mammal, comprising administering to the mammal a recombinant poxvirus vector according to [any one of claims] claim 24 [to 31], thereby eliciting an immune response to the TAA in the mammal.

A6

34. A method according to claim 32 [or claim 33], wherein the TAA is heterologous to the mammal.

Please add the following new claims:

A7 cont

--41. A method for eliciting an immune response in a mammal, comprising administering to the mammal a recombinant poxvirus vector according to claim 26, thereby eliciting an immune response to the TAA in the mammal.

42. A method for breaking immune tolerance against a weak immunogen, comprising administering to a patient having such immune tolerance a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, wherein said vector comprises a nucleic acid sequence which encodes said weak immunogen.

A7 cncld.

43. A vector according to claim 30, wherein the TAA is MART-1 or gp100.

44. A kit used for treating disease, comprising a vector encoding 5T4 antigen and an agent capable of binding 5T4, wherein said agent is fused with an immunostimulatory molecule.

45. A kit used for treating disease, comprising a vector encoding 5T4 antigen and a prodrug/enzyme combination.--